Research programme: respiratory disorder therapeutics - Ipsen BioinnovationAlternative Names: SXN 100187; SXN 187
Latest Information Update: 17 Jul 2015
At a glance
- Originator Syntaxin
- Class Bacterial toxins; Botulinum toxins; Endopeptidases; Recombinant fusion proteins
- Mechanism of Action Mucin inhibitors; SNARE protein antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Bronchitis; Chronic obstructive pulmonary disease; Cystic fibrosis